APRIL 14, 2026 AT 10:20 AM

Johnson & Johnson (JNJ) Q1 2026 (USD) : EPS 2.70 (exp. 2.68), Revenue 24.1bln (exp. 23.61bln), Net Income 6.61bln (exp. 6.55bln), Current FY Rev. 100.3-101.3bln (prev. 100-101bln; exp. 100.62bln), quarterly dividend +3.1% to 1.34/shr (prev. 1.30/shr)

Importance

Level 1

Growth was driven primarily by DARZALEX (GMAB DC), CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology.
Innovative Medicine worldwide operational sales grew 7.4%*, with net acquisitions and divestitures positively impacting growth by 1.8% primarily due to CAPLYTA.